Reports for TEVA CANADA LIMITED
Company Name
TEVA CANADA LIMITED
Totals |
||
Shortage reports |
2684 |
|
Actual shortage: | 240 (9%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2435 (91%) | |
Discontinuation Reports |
250 |
|
To be discontinued: | 3 (1%) | |
Discontinued: | 247 (99%) | |
Reversed: | 0 (0%) | |
Late reports |
330 (11%) |
|
Overdue reports |
27 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
TEVA-ECTOSONE | 0.1% | LOTION | Actual shortage | 2024-04-25 | 2024-05-03 | 226171 |
TEVA-TOPISONE | 0.05% | LOTION | Actual shortage | 2024-05-09 | 2024-05-09 | 227462 |
RATIO-TOPISALIC | 20MG 0.5MG | LOTION | Actual shortage | 2024-05-16 | 2024-05-16 | 228146 |
TEVA-SALBUTAMOL HFA | 100MCG | METERED-DOSE AEROSOL | Resolved | 2020-02-07 | 2020-07-30 | 105599 |
TEVA-FLUTICASONE | 50MCG | METERED-DOSE PUMP | Resolved | 2019-07-02 | 2019-08-06 | 88161 |
TEVA-FLUTICASONE | 50MCG | METERED-DOSE PUMP | Resolved | 2020-10-01 | 2020-10-15 | 125485 |
TEVA-FLUTICASONE | 50MCG | METERED-DOSE PUMP | Resolved | 2023-02-16 | 2023-04-28 | 184928 |
RATIO-NYSTATIN | 100000UNIT | OINTMENT | Resolved | 2017-03-17 | 2017-09-05 | 3145 |
RATIO-AMCINONIDE | 0.1% | OINTMENT | Actual shortage | 2017-08-01 | 2018-12-21 | 17796 |
TEVA-MOMETASONE | 0.1% | OINTMENT | Resolved | 2017-11-16 | 2018-01-04 | 29441 |
TEVA-PROCTOSONE | 5MG 5MG 10MG 10MG | OINTMENT | Actual shortage | 2019-07-02 | 2021-01-14 | 88222 |
TEVA-PROCTOSONE | 5MG 5MG 10MG 10MG | OINTMENT | Actual shortage | 2019-07-02 | 2021-01-14 | 88225 |
TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2020-01-24 | 2020-02-13 | 104368 |
TEVA-CLOBETASOL | 0.05% | OINTMENT | Resolved | 2020-01-30 | 2020-04-09 | 104917 |
TEVA-CLOBETASOL | 0.05% | OINTMENT | Resolved | 2020-03-12 | 2020-04-09 | 108598 |
TEVA-TOPILENE | 0.5MG | OINTMENT | Resolved | 2020-03-26 | 2020-10-08 | 109629 |
TEVA-CLOBETASOL | 0.05% | OINTMENT | Resolved | 2020-05-01 | 2020-06-11 | 113788 |
TEVA-TOPILENE | 0.05% | OINTMENT | Resolved | 2020-06-25 | 2020-10-01 | 118948 |
TEVA-CLOBETASOL | 0.05% | OINTMENT | Resolved | 2020-08-27 | 2020-09-25 | 123084 |
TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2020-09-11 | 2020-10-01 | 124107 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
TEVA-ATORVASTATIN | 40MG | TABLET | Discontinued | 2018-10-17 | 2018-10-17 | 64541 |
TEVA-ATORVASTATIN | 10MG | TABLET | Discontinued | 2018-10-17 | 2018-10-17 | 64601 |
TEVA-ATORVASTATIN | 10MG | TABLET | Discontinued | 2018-10-17 | 2018-10-17 | 64606 |
TEVA-ATORVASTATIN | 20MG | TABLET | Discontinued | 2018-10-17 | 2018-10-17 | 64609 |
TEVA-ATORVASTATIN | 20MG | TABLET | Discontinued | 2018-10-17 | 2018-10-17 | 64612 |
TEVA-QUETIAPINE | 100MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64846 |
TEVA-QUETIAPINE | 25MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64849 |
TEVA-ENALAPRIL | 8MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64855 |
TEVA-ENALAPRIL | 8MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64858 |
TEVA-ENALAPRIL | 8MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64861 |
TEVA-ENALAPRIL | 16MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64866 |
TEVA-ENALAPRIL | 4MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64869 |
TEVA-LISINOPRIL (TYPE P) | 5MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64909 |
NOVO-PROFEN | 400MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64920 |
TEVA-CLONAZEPAM | 0.5MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64923 |
TEVA-CLONAZEPAM | 0.5MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64926 |
TEVA-CLONAZEPAM | 2MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64929 |
TEVA-HYDROMORPHONE | 1MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64970 |
TEVA-HYDROMORPHONE | 2MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64975 |
TEVA-HYDROMORPHONE | 4MG | TABLET | Discontinued | 2018-10-19 | 2018-10-19 | 64983 |